The first general method of direct and highly stereoselective Ti-mediated Mannich reaction between three types of simpleesters and E and Z mixtures of oxime ethers (aliphatic and aromatic) is accomplished.
Diastereoselective Addition of Chlorotitanium Enolate of <i>N</i>-Acyl Thiazolidinethione to <i>O</i>-Methyl Oximes: A Novel, Stereoselective Synthesis of α,β-Disubstituted β-Amino Carbonyl Compounds via Chiral Auxiliary Mediated Azetine Formation
作者:Narendra B. Ambhaikar、James P. Snyder、Dennis C. Liotta
DOI:10.1021/ja029871u
日期:2003.4.1
thiazolidin-2-thiones to O-methyl aldoximes. The “anti” azetines can be subsequently converted to the corresponding α,β-disubstituted β-amino carbonyl compound with retention of stereochemistry. The formation of azetine and the product of its “hydrolytic” opening has been confirmed by X-ray crystallographic analyses.
Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods
申请人:Lundquist, JR. Gregory D.
公开号:US20100240693A1
公开(公告)日:2010-09-23
Thiazolo[
4,5
-c]ring compounds, (e.g. thiazolopyridine, thiazoloquinoline,
6,7,8,9
-tetrahydrothiazoloquinoline, thiazolonaphthyridine, and
6,7,8,9
-tetrahydrothiazolonaphthyridine compounds) having an oxime or hydroxylamine substituent at the
2
-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.